TheraRadar
← Back
Data updated: Nov 8, 2026

AICURIS ANTI-INFECT

Pharma
Infectious Disease Execution: Good

AICURIS ANTI-INFECT is a pharmaceutical company focused on Infectious Disease. Key products include HOVILPRI.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

AICURIS ANTI-INFECT at a Glance

  • Fast trial execution (11 months median completion)

AICURIS ANTI-INFECT's Key Drugs

AICURIS ANTI-INFECT's core commercial portfolio centers on HOVILPRI, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.

HOVILPRI
Approved 2026

AICURIS ANTI-INFECT's Recent FDA Approvals

AICURIS ANTI-INFECT secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

HOVILPRI NDA
2026-10-09
pritelivir mesylate

AICURIS ANTI-INFECT's Therapeutic Areas

AICURIS ANTI-INFECT's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 100%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1

AICURIS ANTI-INFECT's Top Competitors

AICURIS ANTI-INFECT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Infectious Disease
Merck big-pharma
Infectious Disease
Baxter specialty
Infectious Disease
AbbVie big-pharma
Infectious Disease
Johnson & Johnson big-pharma
Infectious Disease

AICURIS ANTI-INFECT Pipeline Snapshot

AICURIS ANTI-INFECT has 3 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 1 Phase 1.

1
Phase 3
1
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • HOVILPRI leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/1 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges